{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:30:05Z","timestamp":1776846605955,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guardant Health Japan Corp."},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013420","name":"Tsumura and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013420","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008645","name":"Terumo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016568","name":"Nippon Zoki Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MedPeer"},{"name":"Merck Biopharma"},{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takata Pharmaceutical"},{"name":"Nihon Servier"},{"DOI":"10.13039\/100030779","name":"Zeria Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030779","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10147-026-02999-z","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:00:11Z","timestamp":1772636411000},"page":"851-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum"],"prefix":"10.1007","volume":"31","author":[{"given":"Ryosuke","family":"Kawagoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-122X","authenticated-orcid":false,"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uetake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Suto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Takii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Komoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunitoshi","family":"Shigeyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamichi","family":"Denda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2999_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2999_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 360:1408\u20131417. https:\/\/doi.org\/10.1056\/NEJMoa0805019","journal-title":"New Engl J Med"},{"key":"2999_CR3","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075. https:\/\/doi.org\/10.1016\/S1470-2045(14)70330-4","journal-title":"Lancet Oncol"},{"key":"2999_CR4","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing S, Modest DP, Rossius L et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17:1426\u20131434. https:\/\/doi.org\/10.1016\/S1470-2045(16)30269-8","journal-title":"Lancet Oncol"},{"key":"2999_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","volume":"32","author":"AP Venook","year":"2014","unstructured":"Venook AP, Niedzwiecki D, Lenz H-J et al (2014) CALGB\/SWOG 80405: phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32:LBA3-LBA3. https:\/\/doi.org\/10.1200\/jco.2014.32.18_suppl.lba3","journal-title":"J Clin Oncol"},{"key":"2999_CR6","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705. https:\/\/doi.org\/10.1200\/JCO.2009.27.4860","journal-title":"J Clin Oncol"},{"key":"2999_CR7","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"LS Schwartzberg","year":"2014","unstructured":"Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240\u20132247. https:\/\/doi.org\/10.1200\/JCO.2013.53.2473","journal-title":"J Clin Oncol"},{"key":"2999_CR8","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713. https:\/\/doi.org\/10.1200\/JCO.2009.27.6055","journal-title":"J Clin Oncol"},{"key":"2999_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713\u20131729. https:\/\/doi.org\/10.1093\/annonc\/mdx175","journal-title":"Ann Oncol"},{"key":"2999_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271\u20131282. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"JAMA"},{"key":"2999_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663\u2013671. https:\/\/doi.org\/10.1200\/JCO.2008.20.8397","journal-title":"J Clin Oncol"},{"key":"2999_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-011-1061-6","volume":"138","author":"CH K\u00f6hne","year":"2012","unstructured":"K\u00f6hne CH, Hofheinz R, Mineur L et al (2012) First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 138:65\u201372. https:\/\/doi.org\/10.1007\/s00432-011-1061-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"2999_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","volume":"15","author":"TJ Price","year":"2014","unstructured":"Price TJ, Peeters M, Kim TW et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569\u2013579. https:\/\/doi.org\/10.1016\/S1470-2045(14)70118-4","journal-title":"Lancet Oncol"},{"key":"2999_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.04.014","volume":"135","author":"D Sakai","year":"2020","unstructured":"Sakai D, Taniguchi H, Sugimoto N et al (2020) Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). Eur J Cancer 135:11\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.014","journal-title":"Eur J Cancer"},{"key":"2999_CR15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1007\/s10147-022-02208-7","volume":"27","author":"T Ito","year":"2022","unstructured":"Ito T, Takashima A, Yamazaki K et al (2022) Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol 27:1450\u20131458. https:\/\/doi.org\/10.1007\/s10147-022-02208-7","journal-title":"Int J Clin Oncol"},{"key":"2999_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41416-018-0165-z","volume":"119","author":"M Peeters","year":"2018","unstructured":"Peeters M, Price T, Taieb J et al (2018) Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer 119:303\u2013312. https:\/\/doi.org\/10.1038\/s41416-018-0165-z","journal-title":"Br J Cancer"},{"key":"2999_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s11523-016-0445-6","volume":"11","author":"A Tsuji","year":"2016","unstructured":"Tsuji A, Sunakawa Y, Ichikawa W et al (2016) Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX plus cetuximab (JACCRO CC-05). Target Oncol 11:799\u2013806. https:\/\/doi.org\/10.1007\/s11523-016-0445-6","journal-title":"Target Oncol"},{"key":"2999_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, K\u00f6hne CH et al (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:692\u2013700. https:\/\/doi.org\/10.1200\/JCO.2014.59.4812","journal-title":"J Clin Oncol"},{"key":"2999_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/btt.s1980","volume":"2","author":"GP Kim","year":"2008","unstructured":"Kim GP, Grothey A (2008) Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics 2:223\u2013228. https:\/\/doi.org\/10.2147\/btt.s1980","journal-title":"Biologics"},{"key":"2999_CR20","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1016\/j.clcc.2019.06.001","volume":"18","author":"O Margalit","year":"2019","unstructured":"Margalit O, Shacham-Shmueli E, Lawrence YR et al (2019) Lung metastasis predicts better prognosis in metastatic colorectal cancer with mutated KRAS. Clin Colorectal Cancer 18:e300\u2013e307. https:\/\/doi.org\/10.1016\/j.clcc.2019.06.001","journal-title":"Clin Colorectal Cancer"},{"key":"2999_CR21","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/j.clcc.2019.12.001","volume":"19","author":"P Cavallaro","year":"2020","unstructured":"Cavallaro P, Bordeianou L, Stafford C et al (2020) Impact of single-organ metastasis to the liver or lung and genetic mutation status on prognosis in stage IV colorectal cancer. Clin Colorectal Cancer 19:e8\u2013e17. https:\/\/doi.org\/10.1016\/j.clcc.2019.12.001","journal-title":"Clin Colorectal Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02999-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02999-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02999-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:34:47Z","timestamp":1776843287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02999-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2999"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02999-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naotoshi Sugimoto received honoraria from Chugai pharm, Daiichi Sankyo and Astra Zeneca, and research grant from Chugai pharm, Daiichi Sankyo, and Boehringer. Akihito Tsuji received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Astra Zeneca, Incyte Biosciences Japan, Eisai Co., Ltd., MSD, Ono Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Sun Pharmaceutical Industries Limited, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., Tsumura & Co., Terumo Corporation, Eli Lilly Japan, Nippon Zoki Pharmaceutical Co., Ltd., Novartis Pharma, Bayer Yakuhin, Ltd., Pfizer Japan Inc., Bristol-Myers Squibb, MedPeer, Inc, Merck Biopharma Co., Ltd., Yakult Honsha Co., Ltd., Takata Pharmaceutical Co., Ltd., Nihon Servier Co., Ltd, and Zeria Pharmaceutical Co., Ltd.. Tadamichi Denda received research grant from Ono, Amgen, MSD, Pfizer, and Bristol Myers Squibb. Atsuo Takashima received research grant from MSD, Takeda, Astra Zeneca, Amgen, Eisai, BMS, Seagen, and Ono. All other authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved from the Ethics Committee of the JSCCR. The requirement for informed consent was waived because of the retrospective design of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}